Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
Naslov
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
Identifikator
/unibl/sci/idNaucniRad:24623
Tip
Pronađite slične unoseAcademic Article
Datum
Pronađite slične unose2017-07
Bibliografski citat
R. Fleischmann, E. Mysler, S. Hall, A. Kivitz, R. Moots, Z. Luo, R. DeMasi, K. Soma, R. Zhang, L. Takiya, S. Tatulych, C. Mojcik, S. Krishnaswami, S. Menon, J. Smolen, LJ. Božić, Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial, LANCET, THE, pp. 457 - 468, Jul, 2017
Početna stranica
457
Krajnja stranica
468
Je dio
LANCET, THE
0140-6736
Lista autora
Position: 3201 (39 views)